BioCryst Pharmaceuticals, Inc.
7.65USD
-0.1300 (-1.67%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on BCRX.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $0.12▼ | $0.13 | 2 | 0 |
| Next quarter | $0.13▼ | $0.16 | 2 | 0 |
| Current year | $0.75▲ | $0.66 | 1 | 1 |
| Next year | $0.83▼ | $1 | 0 | 2 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $0.24 | $0.35 | +0.12 (+49.4%) |
| 2026-03-31 | $0.11 | $0.14 | +0.03 (+27.7%) |
| 2025-12-31 | $0.07 | $0.21 | +0.14 (+197.6%) |
| 2025-09-30 | $0.07 | $0.16 | +0.09 (+125.3%) |
140 ratings from 25 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| JP Morgan | Maintained | Neutral | $12 $13 | Sep 30, 2026 |
| RBC Capital | Downgraded from Outperform | Sector Perform | $13 $11 | Sep 10, 2026 |
| Needham | Reiterated | Buy | $16 | Sep 8, 2026 |
| RBC Capital | Maintained | Outperform | $14 $13 | Aug 6, 2026 |
| Wedbush | Maintained | Outperform | $21 $20 | Aug 6, 2026 |
| RBC Capital | Maintained | Outperform | $13 $14 | Jul 7, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $32 | Jun 30, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $27 $29 | Jun 30, 2026 |
| Citizens | Maintained | Market Outperform | $25 $28 | May 7, 2026 |
| Wedbush | Maintained | Outperform | $22 $21 | May 7, 2026 |
| Needham | Maintained | Buy | $18 $16 | May 6, 2026 |
| RBC Capital | Maintained | Outperform | $14 $13 | Jan 30, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $30 $32 | Dec 15, 2025 |
| Citizens | Maintained | Market Outperform | $27 $25 | Nov 5, 2025 |
| Barclays | Maintained | Equal-Weight | $11 $9 | Nov 4, 2025 |
| Needham | Maintained | Buy | $20 $18 | Nov 4, 2025 |
| Cantor Fitzgerald | Maintained | Overweight | $24 $26 | Oct 15, 2025 |
| JMP Securities | Maintained | Market Outperform | $17 $27 | Oct 15, 2025 |
| Needham | Maintained | Buy | $17 $20 | Oct 15, 2025 |
| Needham | Maintained | Buy | $17 | Aug 4, 2025 |
| B of A Securities | Maintained | Buy | $13 $15 | Jul 1, 2025 |
| RBC Capital | Reiterated | Outperform | $13 | Jun 30, 2025 |
| Wedbush | Maintained | Outperform | $16 $18 | Jun 30, 2025 |
| Needham | Reiterated | Buy | $17 | Jun 27, 2025 |
| Needham | Reiterated | Buy | $17 | Jun 25, 2025 |
73 filings from 16 insiders · 20 buy / 2 sell over 6m
Officers and directors of BCRX, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| MILNE JILL C. PH.D.Director | Grant | 1.3k | $9.70 | $12k | Aug 31, 2026 |
| FRANK STEVEN RDirector | Grant | 1.3k | $9.70 | $12k | Aug 31, 2026 |
| STONEHOUSE JON PDirector | Grant | 644 | $9.70 | $6k | Aug 31, 2026 |
| MCKEE AMY EDirector | Grant | 644 | $9.70 | $6k | Aug 31, 2026 |
| MILANO VINCENT JDirector | Grant | 1.2k | $9.70 | $11k | Aug 31, 2026 |
| MILNE JILL C. PH.D.Director | Grant | 15.3k | — | — | Jun 11, 2026 |
| FRANK STEVEN RDirector | Grant | 15.3k | — | — | Jun 11, 2026 |
| GALSON STEVEN KDirector | Grant | 15.3k | — | — | Jun 11, 2026 |
| STONEHOUSE JON PDirector | Grant | 15.3k | — | — | Jun 11, 2026 |
| MCKEE AMY EDirector | Grant | 15.3k | — | — | Jun 11, 2026 |
| HEGGIE THERESADirector | Grant | 15.3k | — | — | Jun 11, 2026 |
| SANDERS MACHELLEDirector | Grant | 15.3k | — | — | Jun 11, 2026 |
| LEVIN ALAN GDirector | Grant | 15.3k | — | — | Jun 11, 2026 |
| MILANO VINCENT JDirector | Grant | 15.3k | — | — | Jun 11, 2026 |
| MILNE JILL C. PH.D.Director | Grant | 1.3k | $8.91 | $11k | May 29, 2026 |
| FRANK STEVEN RDirector | Grant | 1.3k | $8.91 | $11k | May 29, 2026 |
| STONEHOUSE JON PDirector | Grant | 631 | $8.91 | $6k | May 29, 2026 |
| MCKEE AMY EDirector | Grant | 631 | $8.91 | $6k | May 29, 2026 |
| MILANO VINCENT JDirector | Grant | 1.1k | $8.91 | $10k | May 29, 2026 |
| MCKEE AMY EDirector | Sell | 11.2k | $8.97 | $100k | May 18, 2026 |
No analyst notes on BCRX yet.
Analyst Ratings
11 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 7 | 2 | 0 | 0 | Buy2.00 |
| 1 mo ago | 2 | 7 | 2 | 0 | 0 | Buy2.00 |
| 2 mo ago | 3 | 7 | 1 | 0 | 0 | Buy1.82 |
| 3 mo ago | 3 | 7 | 1 | 0 | 0 | Buy1.82 |
Members whose judged calls on BCRX have played out most reliably.
No settled calls on BCRX yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice